Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season - 04/08/18
Doi : 10.1016/j.jaci.2018.01.052
Alexander Kettner, PhD a, ∗, Gilles DellaCorte, MD a, ∗, ‡, Fréderic de Blay, MD, PhD b, Lars Jacobsen, PhD c, Marek Jutel, MD d, e, Margitta Worm, MD f, Vincent Charlon, PhD a, Kim Simonsen, MD a, Christophe Reymond, PhD a, ‡, François Spertini, MD g 
a Anergis SA, Epalinges, Switzerland
b Chest Diseases Department, Nouvel Hôpital Civil, Strasbourg University Hospital, University of Strasbourg, Strasbourg, France
c Allergy Learning and Consulting, Copenhagen, Denmark
d “ALL-MED” Medical Research Institute, Wroclaw, Poland
e Department of Clinical Immunology, Silesian Piasts University of Medicine, Wroclaw, Poland
f Allergie-Centrum-Charité, Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Berlin, Berlin, Germany
g Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| The study was supported by Anergis SA (Route de la Corniche 9B, 1066 Epalinges, Switzerland), the developer of Bet v 1 COP. |
|
| Disclosure of potential conflict of interest: F. de Blay reports grants from Stallergenes-Greer and Chiesi and personal fees from ALK, Mundipharma, and Novartis, during the conduct of the study; and is a board member for Stallergenes-Greer, Novartis, ALK, Mundipharma, Medapharma, Boehringer, and Teva. M. Jutel reports lecture fees from ALK-Abello; lecture fees, advisory board, and clinical investigator fees from Allergopharma; lecture fees and clinical investigator fees from Stallergenes; advisory board and clinical investigator fees from Anergis; advisory board fees from Biomay and UCB; and clinical investigator fees from HAL, Astra-Zeneka, GSK, Novartis, Teva, Vectura, Tekada, Roche, Janssen, Medimmune, Allergy Therapeutics, Circassia, Leti, and Chiesi. L. Jacobsen and M. Worm received money for consulting fees and study preparation from Anergis SA. L. Jacobsen received money for study preparation from Anergis SA. M. Worm was paid for consultancy outside of this research by Anergis SA. A. Kettner, G. DellaCorte, V. Charlon, C. Reymond, and K. Simonsen are employees of Anergis SA and have stock options with this company. V. Charlon received travel/accommodations/meeting expenses from Anergis SA unrelated to this research. F. Spertini has stock/stock options with Anergis SA; received support for travel to meetings for the study or other purposes from Anergis SA; has patents (planned, pending, or issued) and received royalties from CHUV, Lausanne, CH; and is a funder of the company Anergis SA, which supported this study. |
© 2018
Publié par Elsevier Masson SAS.
Vol 142 - N° 2
P. 678 - août 2018 Retour au numéro
Article précédent
- Transcutaneous CO-oximetry differentiates asthma exacerbation and convalescence in children
- David B. Kantor, Carter R. Petty, Wanda Phipatanakul, Jonathan M. Gaffin
- Thromboxane A2 facilitates IL-17A production from V?4+ ?? T cells and promotes psoriatic dermatitis in mice
- Yuri Ueharaguchi, Tetsuya Honda, Nobuhiro Kusuba, Sho Hanakawa, Akimasa Adachi, Yu Sawada, Atsushi Otsuka, Akihiko Kitoh, Teruki Dainichi, Gyohei Egawa, Chisa Nakashima, Saeko Nakajima, Teruasa Murata, Sachiko Ono, Makoto Arita, Shuh Narumiya, Yoshiki Miyachi, Kenji Kabashima
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?